Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma FDA Decision: The Oncology Institute, Inc. (TOI)

The Phase 3 date for Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma by The Oncology Institute, Inc. (TOI) is scheduled for December 31, 2028. This is the target date for the FDA to make a decision on this application.

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma is being developed by The Oncology Institute, Inc. for the treatment of its target indication. It is currently in Phase 3 clinical trials.

If Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma receives FDA approval, The Oncology Institute, Inc. (TOI) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Phase 3 date closely.

Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for TOI on DilutionWatch at dilutionwatch.com/stock/TOI.html.

You can view the full BiotechSign company profile for The Oncology Institute, Inc. (TOI) at biotechsign.com/app/company/TOI, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.